

Cancer risk assessment tools for symptomatic individuals presenting to primary care: a systematic scoping review

Cancer Research UK (CRUK) 5th Biennial Early Diagnosis Research Conference, The Hilton Birmingham Metropole, 11-13th February 2019

Dr Joseph Akanuwe, Prof Niro Siriwardena, Dr Sharon Black, Prof Sara Owen

Contact: jakanuwe@Lincoln.ac.uk

Background

 Cancer risk assessment tools designed to predict cancer risk in symptomatic individuals in primary care settings are being advocated to address the problem of late diagnosis of cancer in the UK

• Little is known about the use and implementation of cancer risk assessment tools to aid early detection of cancer risk in general practice



 We aimed to scope the evidence on the type of cancer risk assessment tools available for symptomatic individuals, and the current use of the tools including the benefits and barriers to their use.

Methods

• Using Arksey and O'Malley's framework, we conducted a systematic scoping review of published literature in the English language from 2004 to 2017

• We searched six electronic databases (Medline, CINAHL, Scopus, Cochrane, Science Direct and Psych-INFO) and other sources using specific search terms e.g Cancer risk assess* tool* AND use or implement* AND symptom* or patient* AND clinician* or general Pract* or primary care or family practice) AND benefit or impact*

• A narrative synthesis was used to summarise the findings from the studies identified.

Results

• We retrieved a total of 471 papers from the electronic databases and 43 studies matched the inclusion criteria following a title, abstract and full-text screen by three reviewers – one checking where there was disagreement (see flow chart below)

Title & abstract sift of 471 studies

415 studies filtered out after title & abstract sift

- Novel cancer risk assessment tools for symptomatic individuals in primary care identified from the review included the QCancer and RAT series
- While there was some evidence supporting use of some of the tools, there was limited evidence on the current use and the impact of using the tools on patient outcomes such as rates of cancer diagnosis and survival

56 studies full text studies retrieved and sifted

13 studies excluded after filtering out duplicates

43 studies selected for the review

 There was also some evidence on potential benefits and barriers to using the tools in primary care consultations (see Table below).

Benefits and barriers to implementing cancer risk assessment tools	
Benefits	 Potential aid for clinicians to confirm investigations and referral decisions
	 Reassurance of patients when investigation not needed
	 Helping GPs to recognise symptoms of some cancers
	 Useful for detecting cancer risk in patients with complex histories.
Barriers	 How to make the tools available to clinicians
	 How best to communicate cancer risk information to patients
	 Uncertainty about the threshold for action to be taken
	 Extra consultation time requirement
	 Potential for causing alarm to patients
	Detential burden en recourses

- Potential burden on resources
- Challenge about integrating the tools into general practice workflow
- Potential for 'prompt fatigue.

Conclusions

- The review revealed evidence of novel cancer risk assessment tools designed for symptomatic individuals in primary care
- There was also evidence on potential benefits and barriers relating to the use of the tools
- There is a need to address the barriers identified when implementing the tools in general consultations.

CaHRU@lincoln.ac.uk



